Report for Park SI

General

Full name :

First name :

Mail :

Zip Code :

City :

Country :

Email :

Phone :

Fax :

Website :

Directory :

References (2)

Title : Therapeutic strategy targeting host lipolysis limits infection by SARS-CoV-2 and influenza A virus - Baek_2022_Signal.Transduct.Target.Ther_7_367
Author(s) : Baek YB , Kwon HJ , Sharif M , Lim J , Lee IC , Ryu YB , Lee JI , Kim JS , Lee YS , Kim DH , Park SI , Kim DK , Choy HE , Lee S , Choi HS , Osborne TF , Jeon TI , Cho KO
Ref : Signal Transduct Target Ther , 7 :367 , 2022
Abstract : Baek_2022_Signal.Transduct.Target.Ther_7_367
ESTHER : Baek_2022_Signal.Transduct.Target.Ther_7_367
PubMedSearch : Baek_2022_Signal.Transduct.Target.Ther_7_367
PubMedID: 36253361

Title : Pharmacokinetic comparison using two tablets of an evogliptin\/metformin XR 2.5\/500 mg fixed dose combination vs. 1 tablet each of evogliptin 5 mg and metformin XR 1,000 mg - Yoon_2017_Int.J.Clin.Pharmacol.Ther_55_533
Author(s) : Yoon S , Rhee SJ , Park SI , Yoon SH , Cho JY , Jang IJ , Lee S , Yu KS
Ref : Int J Clinical Pharmacology & Therapeutics , 55 :533 , 2017
Abstract : Yoon_2017_Int.J.Clin.Pharmacol.Ther_55_533
ESTHER : Yoon_2017_Int.J.Clin.Pharmacol.Ther_55_533
PubMedSearch : Yoon_2017_Int.J.Clin.Pharmacol.Ther_55_533
PubMedID: 28406090